SXTP SXTP
Company Profile ↓Company Overview
SXTP (SXTP) is a publicly traded company listed on with a market capitalization of $1.42M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 65.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $1.01M (+65.5% YoY); net profit $-7.37M.
- Trailing 12 Months Year-on-year growth — revenue +65.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 65.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 65.15% |
| 1 Year: | 65.49% |
Stock Price Performance
| 1 Year: | -77.07% |
| 6 Months: | -69.65% |
| 3 Months: | -26.06% |
| 1 Month: | -24.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 65.1% over 5 years.
CONS
- Trading 83.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.17K | 168.19K | 17.17K | 59.53K | 51.19K | 105.67K | 124.97K | 135.29K | - | 163.55K | 100.93K | 437.60K | 303.38K | 162.09K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 73.27K | 50.05K | 537.69K | 120.68K | 85.72K |
| Gross Profit | - | - | -55.95K | -124.44K | -20.01K | 40.24K | 35.41K | 23.61K | - | 90.28K | 50.88K | -100.09K | 182.70K | 76.38K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 2.00M | 1.66M | 2.23M | 2.10M | 2.17M |
| Operating Income | -686.92K | -215.12K | -950.66K | -788.00K | -1.52M | -1.34M | -4.19M | -2.12M | - | -1.91M | -1.60M | -2.33M | -1.92M | -2.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | -1.86M | -1.71M | -2.29M | -1.41M | -2.06M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 1.79K | 1.22K | 1.71K | 3.09K | 1.39K |
| Pretax Income | - | - | - | - | - | - | - | - | - | -1.88M | -1.73M | -2.32M | -1.44M | -2.09M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 0 | 1.50K | 250 | -1.81K | 0 |
| Net Income | -2.15M | -1.45M | -2.60M | -3.34M | 4.18M | 430.47K | -4.17M | -2.16M | - | -1.88M | -1.73M | -2.32M | -1.44M | -2.09M |
| Diluted EPS | -0.96 | -0.61 | -1.13 | -16.84 | 9.13 | 1.83 | -21.12 | -2.92 | - | -6.25 | -5.00 | -2.52 | - | -1.28 |
| R&D Expense | 231.39K | 27.66K | 123.99K | 203.87K | 263.70K | 337.18K | 3.10M | 940.06K | - | 370.81K | 249.88K | 809.78K | - | 281.46K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 223.21K | 253.57K | 607.57K | 1.01M |
| Cost of Revenue | - | 432.37K | 474.55K | 384.76K | 781.70K |
| Gross Profit | - | -209.16K | -220.98K | 222.81K | 223.78K |
| Operating Expenses | - | 1.54M | 4.93M | 9.94M | 7.98M |
| Operating Income | - | -1.75M | -5.15M | -9.72M | -7.76M |
| EBITDA | - | -2.11M | -1.43M | -7.88M | -7.28M |
| Interest Expense | - | 3.99M | 2.29M | 7.91K | 7.80K |
| Pretax Income | - | -6.18M | -3.81M | -7.96M | -7.37M |
| Tax Provision | - | 500 | 250 | 0 | 0 |
| Net Income | - | -6.18M | -3.77M | -7.95M | -7.37M |
| Diluted EPS | - | -266.38 | -236.72 | -74.17 | -11.73 |
| R&D Expense | - | 525.56K | 691.77K | 4.99M | 2.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.30M | 7.78M | 5.76M | 5.37M |
| Current Assets | - | 1.10M | 7.24M | 5.39M | 4.90M |
| Cash & Equivalents | - | 264.87K | 2.14M | 1.66M | 1.51M |
| Inventory | - | 518.58K | 466.17K | 442.76K | 656.92K |
| Receivables | - | 45.97K | 231.33K | 486.75K | 509.64K |
| Total Liabilities | - | 25.45M | 2.99M | 1.80M | 1.99M |
| Current Liabilities | - | 23.92M | 2.84M | 1.66M | 1.84M |
| Long Term Debt | - | 1.27M | 150.25K | 147.12K | 144.00K |
| Total Debt | - | 22.42M | 172.67K | 155.89K | 152.78K |
| Total Equity | - | -23.58M | 4.87M | 4.04M | 3.46M |
| Shares Outstanding | - | 23.21K | 24.21K | 141.73K | 1.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.01M | -4.54M | -5.65M | -6.85M |
| Investing Cash Flow | - | -60.13K | -115.89K | -1.89M | 254.92K |
| Financing Cash Flow | - | 1.22M | 6.47M | 7.05M | 6.44M |
| Capital Expenditure | - | -60.13K | -115.89K | -181.11K | -218.08K |
| Free Cash Flow | - | -1.07M | -4.66M | -5.83M | -7.07M |
| Net Change in Cash | - | 151.59K | 1.82M | -483.63K | -156.41K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -93.7% | -87.1% | 36.7% | 22.3% |
| Operating Margin % | - | -784.2% | -2,032.8% | -1,599.0% | -771.6% |
| Net Margin % | - | -2,769.5% | -1,485.1% | -1,308.0% | -732.5% |
| ROE % | - | 26.2% | -77.3% | -196.9% | -212.7% |
| ROCE % | - | 7.7% | -104.2% | -236.8% | -220.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SXTP
Lind Global Fund III (SXTP) discloses 5.45% stake with warrant conversion cap - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQUWF5Q2d6MGhhU1kzQXNyX1RtTTVCeG1xX1JNbVhtVHZ2NW9EOHVld0x1QklLMWVsakZvVEszbVdPWlFBOW40cnExNXJ3d05scnExNmRTblVRQnhQMkhkQUFheHJOX1BUNjljcVgycjg5X2lOd0xpUjAzOXdsbUxyQkMzbjBVVXBqSkU3UV…
60 Degrees Pharmaceuticals Announces $1.0 Million Private Placement of Common Stock and Warrants - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNTTVZWkxjXzhzMi1oMXczNk9TUEZFMWduY2V0dlBJUWNWN1V5eGdramN5dnc1eGNwVGc5Zi0xNTkyMXBJalVlMzBNbW94U1BEMG1UVGVmUzJ4a0EyaGRCQzd4WDkyMXZxYm9YTWZmV04yRDBXbTlXVnFaTUJnMHlXX1NtYVhsaTgwVnVLZF…
60 Degrees Pharmaceuticals Raises $1.0 Million in Private Placement of Stock and Warrants - TradingView
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOaWRDbGsxUXRZX0VmSFlBTDNIVzBfdUFDX3F6WEoxQjBJY0Q4UDlScDZqUzcwYU1sakt0NmRzbUZuM3c1cmgzSm9ZX0F0Rk5JVXNDUFBOYTZNWEptbXlVbTJZb19IWkZXd0VZNTRfRFl1QWxIaDB0b1ZyaEhTOER0clN6VDR1S2xoWkpyY2…
SXTP|60 Degrees Pharmaceuticals Inc|Price:1.140|Chg%:-0.030 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE4tLXFkNEl2VDhmNGw5LXRRMzJnZ28tT01YZ0hXUUNoMUIxdWR5enlKRXktSzlTdGV2TkJrcXBEREFaQTdaRTc3VlJvbWV0X2RJUGVkckdueVY5Rk9RZW11VXZFdjVxLWpTeURNdDV3?oc=5" target="_blank">SXTP|60 Degrees Pha…
60 Degrees Pharmaceuticals (NASDAQ: SXTP) raises $1M in warrant-backed private placement - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTEZkQWN4MnpNWGVuLVhmMWs0Q0VXcXBvMEUwX0JzSEN0bEt3ZWxtUGpfNk5ZbURpZ2d3dFE0bmlhZFJsSHZsOTNNaE9KZDdnOUItUmFuZ0ZPdzJVRXBtVjJjS1BqbzhTb01RRjZDSWQ1YnZ2d09CVVlnZWdOS0R0OElnSmNrc3FDUU11R2…
SXTP Stock Dips Amid Earnings Shake: Investors On Edge - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQZGZ3SFBOWE5nWDdsZkQzaDc2RTE2Q2J6MVo0OEtDRFpjdVhTaEhETHJicVV2Q243VkdIMG02R1JXbVNXSTg1bWRGZDEtblVqU1BOYVhuUzUwRktIcHVzczdOVkxUdnE4c1kxZDZ5VzFtanlRMDZQR3dHMjJFUlRjNUFOOTNxYVFfNmc?oc…
SXTP — Frequently Asked Questions
What is the current share price of SXTP?
As of 2026-08-05 17:25 PDT, SXTP trades at $1.22 on NASDAQ/NYSE. Its 52-week range is $1.16 to $7.20.
What is the market capitalisation of SXTP?
SXTP has a market capitalisation of $1.42M on NASDAQ/NYSE.
What is the P/E ratio of SXTP?
SXTP trades at a trailing price-to-earnings (P/E) ratio of -0.10. Its price-to-book (P/B) ratio is 0.41.
Is SXTP a good stock to buy?
This page provides a data-driven analysis of SXTP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.